These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25979770)

  • 21. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.
    Serrano-Mendioroz I; Sampedro A; Alegre M; Enríquez de Salamanca R; Berraondo P; Fontanellas A
    Hum Gene Ther; 2018 Apr; 29(4):480-491. PubMed ID: 28990424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of Total Vitamin-D-Binding Protein and the Glycosylated Isoforms by Liquid Chromatography-Isotope Dilution Mass Spectrometry.
    Kilpatrick LE; Phinney KW
    J Proteome Res; 2017 Nov; 16(11):4185-4195. PubMed ID: 28990783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular diagnostics of acute intermittent porphyria.
    Kauppinen R
    Expert Rev Mol Diagn; 2004 Mar; 4(2):243-9. PubMed ID: 14995910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy.
    Carichon M; Pallet N; Schmitt C; Lefebvre T; Gouya L; Talbi N; Deybach JC; Beaune P; Vasos P; Puy H; Bertho G
    Anal Chem; 2014 Feb; 86(4):2166-74. PubMed ID: 24437734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
    Barreda-Sánchez M; Buendía-Martínez J; Glover-López G; Carazo-Díaz C; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Rodriguez-Peña L; Serrano-Antón AT; Gil-Ferrer R; Martínez-Romero MDC; Carbonell-Meseguer P; Guillén-Navarro E
    Orphanet J Rare Dis; 2019 Feb; 14(1):59. PubMed ID: 30808393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.
    Yasuda M; Bishop DF; Fowkes M; Cheng SH; Gan L; Desnick RJ
    Mol Ther; 2010 Jan; 18(1):17-22. PubMed ID: 19861948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria.
    Pulgar VM; Yasuda M; Gan L; Desnick RJ; Bonkovsky HL
    Mol Genet Metab; 2019 Nov; 128(3):376-381. PubMed ID: 30639047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circadian rhythms in acute intermittent porphyria--a pilot study.
    Larion S; Caballes FR; Hwang SI; Lee JG; Rossman WE; Parsons J; Steuerwald N; Li T; Maddukuri V; Groseclose G; Finkielstein CV; Bonkovsky HL
    Eur J Clin Invest; 2013 Jul; 43(7):727-39. PubMed ID: 23650938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria.
    Vera-Yunca D; Córdoba KM; Parra-Guillen ZP; Jericó D; Fontanellas A; Trocóniz IF
    Br J Pharmacol; 2022 Jul; 179(14):3815-3830. PubMed ID: 35170015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
    Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
    J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular genetic study of acute intermittent porphyria in Russia: mutation analysis and functional polymorphism search in porphobilinogen deaminase gene].
    Surin VL; Luchinina IuA; Selivanova DS; Pustovoĭt IaS; Karpova IS; Pivnik AV; Luk'ianenko AV; Kravchenko SK
    Genetika; 2010 Apr; 46(4):540-52. PubMed ID: 20536026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating fluorocytes at the first attack of acute intermittent porphyria: a missing link in the pathogenesis.
    Lam CW; Lau KC; Mak CM; Tsang MW; Chan YW
    Clin Chim Acta; 2011 Jan; 412(1-2):208-12. PubMed ID: 20850424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute intermittent porphyria: Long-term follow up of 35 patients].
    Herrero C; Badenas C; Aguilera P; To-Figueras J
    Med Clin (Barc); 2015 Oct; 145(8):332-7. PubMed ID: 25194977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.
    Prabahar MR; Manorajan R; Sathiyakumar D; Soundararajan P; Jayakumar M
    Hemodial Int; 2008 Jan; 12(1):34-8. PubMed ID: 18271838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.
    Chen B; Wang M; Gan L; Zhang B; Desnick RJ; Yasuda M
    Mol Genet Metab; 2019 Nov; 128(3):382-390. PubMed ID: 30777612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute intermittent porphyria.
    Grandchamp B
    Semin Liver Dis; 1998; 18(1):17-24. PubMed ID: 9516674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria.
    Gross U; Jacob K; Frank M; Doss MO
    Cell Mol Biol (Noisy-le-grand); 1997 Feb; 43(1):29-35. PubMed ID: 9074786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Three new mutations in the porphobilinogen deaminase gene, detected in acute intermittent porphyria patients from Russia].
    Surin VL; Luk'ianenko AV; Karpova IV; Misiurin AV; Pustovot IaS; Pivnik AV
    Genetika; 2001 May; 37(5):690-7. PubMed ID: 11436563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel mutation in a family with non-erythroid variant form of acute intermittent porphyria.
    Yu S; Poulos V; Stewart P
    J Hum Genet; 2000; 45(6):367-9. PubMed ID: 11185747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.
    Córdoba KM; Jericó D; Jiang L; Collantes M; Alegre M; García-Ruiz L; Manzanilla O; Sampedro A; Herranz JM; Insausti I; Martinez de la Cuesta A; Urigo F; Alcaide P; Morán M; Martín MA; Lanciego JL; Lefebvre T; Gouya L; Quincoces G; Unzu C; Hervas-Stubbs S; Falcón-Pérez JM; Alegre E; Aldaz A; Fernández-Seara MA; Peñuelas I; Berraondo P; Martini PGV; Avila MA; Fontanellas A
    Gut; 2024 Nov; ():. PubMed ID: 39366725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.